Mr. Dean Burns reports

OCUMETICS ANNOUNCES CORPORATE AND OPERATIONAL UPDATE AS POSITIVE SIX-MONTH CLINICAL RESULTS ADVANCE NEXT PHASE OF FIRST-IN-HUMAN STUDY

Ocumetics Technology Corp. has provided shareholders with a corporate and operational update highlighting continued progress across its clinical development program, manufacturing activities, regulatory initiatives, financing strategy and commercialization efforts.

Since reporting encouraging initial first-in-human clinical results, the company has continued to execute on multiple strategic initiatives designed to advance the Ocumetics lens toward commercialization. Positive six-month clinical data have supported progression to Group Two surgeries. Manufacturing of the redesigned Ocumetics lens has commenced, regulatory milestones have been achieved and strategic engagement with leading global ophthalmic companies continue to build momentum.

"The past several months have marked one of the most productive periods in Ocumetics's history," commented Dean Burns, president and chief executive officer. "With group two surgeries expected to commence during the third quarter of 2026, we believe the company is entering an important value creation phase as we continue to build long-term shareholder value."

Corporate update

Financing initiative to advance clinical development

To support completion of its FIH clinical study and prepare for subsequent regulatory submissions, the company has launched a financing initiative intended to finance the next phase of clinical development while supporting manufacturing, regulatory and commercialization activities (see news release dated July 7, 2026).

Proceeds are expected to be used to:

• Complete Group Two FIH surgeries in Mexico City;
• Finalize manufacturing and quality verification of clinical lenses for use in the FIH and continuing clinical studies;
• Complete sterilization and packaging activities;
• Advance regulatory and quality assurance programs;
• Continue strategic partnership and commercialization initiatives.

During recent investor conferences, Ocumetics conducted more than 50 one-on-one meetings with institutional investors, family offices, high-net-worth investors, investment bankers/advisers and strategic industry participants. Management believes the continued level of investor engagement reflects growing recognition of the company's clinical progress and long-term commercial opportunity.

Strategic commercialization discussions continue

The company continues to engage with several of the world's leading ophthalmic organizations regarding potential strategic partnerships and commercialization opportunities.

To date, management has met with representatives from four of the world's seven largest ophthalmic companies to introduce the Ocumetics technology platform. Based on encouraging feedback received during these meetings, several organizations have expressed interest in reviewing additional clinical data following completion of Group Two surgeries. Follow-up discussions are tentatively scheduled for early fourth quarter 2026 following the availability of Group Two one-month patient results.

Management believes discussions to date validate the commercial potential of the Ocumetics lens and its ability to address a significant unmet need in vision restoration following cataract surgery.

Operational update

Positive six-month clinical results support advancement to Group Two surgeries

Six-month follow-up data from Group One patients enrolled in the company's FIH clinical study continues to demonstrate encouraging safety and performance outcomes. The surgical team reported successful implantation procedures and favourable postoperative outcomes. The study continues to achieve its primary objectives related to safety, lens delivery and distance vision correction.

Anecdotally, patients have reported meaningful improvements in vision and quality of life, including one individual previously considered to be legally blind that is now qualified to drive.

These positive clinical outcomes have provided the foundation necessary for Ocumetics to advance to the second group of its FIH study (Group Two), representing another significant milestone toward commercialization.

Next-generation Ocumetics lens completed

Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens, representing years of research, engineering and product refinement.

The redesigned lens incorporates significant advancements intended to improve manufacturability, surgical handling, long-term reliability and accommodative performance while simplifying future commercial production.

Expected benefits of the redesigned Ocumetics lens include:

• Enhanced accommodative performance;
• Simplified lens architecture with one-piece design;
• Improved manufacturing consistency;
• Elimination of internal interface materials: no air, water or oil;
• Optimized surgical implantation characteristics;
• Improved compatibility with the redesigned lens delivery system;
• Greater scalability for commercial manufacturing.

The company intends to use this redesigned lens for the coming Group Two FIH study surgeries.

Manufacturing and regulatory progress

Manufacturing of the redesigned Ocumetics lens has commenced with the company's German manufacturing partner, Amiplant GmbH.

Coming activities include finalization of manufacturing, product verification, sterilization, product packaging and release of clinical inventory ahead of the planned third quarter 2026 clinical surgeries.

Ocumetics has completed all regulatory requirements necessary to proceed to Group Two patient enrolment. Working closely with its clinical investigators, ethics committees and regulatory consultants, the company has completed the regulatory processes required to advance the study.

Upon completion of manufacturing and product release activities, patient recruitment and surgical scheduling will commence.

Group Two FIH surgeries

Following the successful completion of Group One surgeries and encouraging six-month clinical results, Ocumetics continues preparations for Group Two FIH surgeries, which remain on schedule for Q3 2026 in Mexico City under the leadership of principal investigator Dr. Raphael Vasquez and his experienced surgical team.

Group Two patients are expected to receive the redesigned Ocumetics lens delivered with the company's updated lens delivery system. The Ocumetics lens and the lens delivery system each incorporate improvements developed through previous preclinical work and feedback from the Group One FIH surgery experience.

Management believes positive one-month results of the Group Two patients will represent another meaningful value creation milestone for Ocumetics as the company advances toward its larger clinical studies, future regulatory submissions and eventual commercialization.

Looking ahead

With positive six-month clinical data, completion of the next-generation lens design, manufacturing under way, regulatory milestones achieved and strategic commercialization discussions continuing with leading global ophthalmic companies, Ocumetics believes it is well positioned to execute the next phase of its clinical development strategy.

Management remains focused on completing Group Two FIH surgeries, advancing regulatory initiatives and continuing to build strategic relationships that support the long-term commercialization of the Ocumetics lens.

About Ocumetics Technology Corp.

Ocumetics is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed a dynamic intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses, and without perceptible time lag.

We seek Safe Harbor.